Kun-Huei Yeh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5892050/publications.pdf

Version: 2024-02-01

162 papers	9,329 citations	109321 35 h-index	42399 92 g-index
166 all docs	166 docs citations	166 times ranked	11528 citing authors

#	Article	IF	Citations
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	13.7	1,749
2	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
3	p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Current Biology, 1999, 9, 661-S2.	3.9	850
4	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 619-629.	10.7	574
5	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANâ€"A Randomized, Phase III Study. Journal of Clinical Oncology, 2014, 32, 2039-2049.	1.6	524
6	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	1.6	524
7	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	10.7	418
8	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 2013, 31, 3935-3943.	1.6	411
9	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 2020, 23, 510-519.	5.3	155
10	Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFÎºB activation. Biochemical Pharmacology, 2002, 63, 1423-1430.	4.4	126
11	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pyloriâ€"positive gastric diffuse large B-cell lymphomas. Blood, 2012, 119, 4838-4844.	1.4	123
12	High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. International Journal of Cancer, 2002, 101, 519-525.	5.1	109
13	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2008, 68, 6698-6707.	0.9	109
14	Estrogen Receptor Î± Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4Î±. Gastroenterology, 2012, 142, 989-998.e4.	1.3	105
15	Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-ÎºB Activation by Protein Phosphatase 4-mediated NF-ÎºB p65 Thr Dephosphorylation. Journal of Biological Chemistry, 2004, 279, 26143-26148.	3.4	97
16	High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer, 1998, 82, 1626-1631.	4.1	93
17	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology, 1994, 107, 1514-1518.	1.3	86
18	Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene, 2004, 23, 3580-3588.	5.9	83

#	Article	IF	Citations
19	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood, 2005, 106, 1037-1041.	1.4	74
20	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. International Journal of Cancer, 2002, 97, 451-457.	5.1	65
21	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958.	5.3	61
22	Nuclear Expression of BCL10 or Nuclear Factor Kappa B Predicts Helicobacter pyloriâ€"Independent Status of Early-Stage, High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphomas. Journal of Clinical Oncology, 2004, 22, 3491-3497.	1.6	59
23	Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Advanced Gastric Cancers. Oncology, 1997, 54, 275-280.	1.9	56
24	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochemical Pharmacology, 1998, 55, 523-531.	4.4	54
25	Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma. , 1998, 82, 1946-1951.		53
26	The F-Box Protein SKP2 Binds to the Phosphorylated Threonine 380 in Cyclin E and Regulates Ubiquitin-Dependent Degradation of Cyclin E. Biochemical and Biophysical Research Communications, 2001, 281, 884-890.	2.1	53
27	Overexpression of B cellâ€"activating factor of TNF family (BAFF) is associated with Helicobacter pyloriâ€"independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood, 2008, 112, 2927-2934.	1.4	52
28	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment, 2017, 49, 851-868.	3.0	50
29	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 143-153.	5.3	45
30	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. PLoS ONE, 2012, 7, e50701.	2.5	44
31	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64, 346-351.	2.0	43
32	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer, 2016, 16, 327.	2.6	42
33	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. Journal of Clinical Oncology, 2016, 34, 335-335.	1.6	42
34	A Pathway for Tumor Necrosis Factor-Î±-induced Bcl10 Nuclear Translocation. Journal of Biological Chemistry, 2006, 281, 167-175.	3.4	39
35	Involvement of nuclear transcription factor-ÎºB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochemical Pharmacology, 2003, 66, 25-33.	4.4	38
36	Elevated p53 promotes the processing of miRâ€18a to decrease estrogen receptorâ€α in female hepatocellular carcinoma. International Journal of Cancer, 2015, 136, 761-770.	5.1	37

#	Article	IF	Citations
37	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11937-11942.	7.1	37
38	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. Clinical Colorectal Cancer, 2015, 14, 177-184.e4.	2.3	36
39	Nuclear Extracellular Signal-Regulated Kinase 2 Phosphorylates p53 at Thr55 in Response to Doxorubicin. Biochemical and Biophysical Research Communications, 2001, 284, 880-886.	2.1	34
40	Depletion of Î²-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18384-18389.	7.1	33
41	Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer. PLoS ONE, 2017, 12, e0170942.	2.5	33
42	Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma. American Journal of Hematology, 1999, 60, 161-163.	4.1	32
43	Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. Annals of Oncology, 2013, 24, 463-468.	1.2	32
44	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anti-Cancer Drugs, 2004, 15, 371-376.	1.4	31
45	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. , 1996, 77, 872-877.		30
46	Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers, 2019, 11, 547.	3.7	30
47	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. PLoS ONE, 2013, 8, e81922.	2.5	30
48	Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24â€hour infusion of highâ€dose 5â€fluorouracil and leucovorin. British Journal of Haematology, 1998, 100, 769-772.	2.5	29
49	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
50	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7275.	3.3	26
51	Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer. Oncologist, 2014, 19, 951-958.	3.7	24
52	Unmet Supportive Care Needs of Patients With Colorectal Cancer: Significant Differences by Type D Personality. Oncology Nursing Forum, 2014, 41, E3-E11.	1.2	23
53	Panhypopituitarism Caused by Solitary Parasellar Metastasis From Lung Cancer. Chest, 1994, 105, 951-953.	0.8	22
54	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Medical Oncology, 2016, 33, 39.	2.5	22

#	Article	IF	Citations
55	Telomeraseâ€specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. International Journal of Cancer, 2013, 132, 1451-1462.	5.1	21
56	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. Journal of Hematology and Oncology, 2016, 9, 29.	17.0	21
57	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Scientific Reports, 2017, 7, 14333.	3.3	21
58	Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood, 2017, 129, 188-198.	1.4	20
59	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncology, 2018, 14, 2031-2044.	2.4	20
60	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Oncology, 2005, 69, 88-95.	1.9	19
61	Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. American Journal of Surgical Pathology, 2015, 39, 761-766.	3.7	19
62	Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Japanese Journal of Clinical Oncology, 2015, 45, 819-827.	1.3	19
63	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88.	2.3	19
64	Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients. PLoS ONE, 2014, 9, e86789.	2.5	18
65	Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma. Annals of Surgery, 2008, 247, 265-269.	4.2	17
66	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. European Journal of Cancer, 2011, 47, 1244-1257.	2.8	17
67	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer, 2012, 15, 265-280.	5.3	17
68	Expression of CD86 and increased infiltration of NK cells are associated withHelicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma. World Journal of Gastroenterology, 2005, 11, 4357.	3.3	17
69	Authorâ€™s reply: Vitamin A and gastric cancer risk. Gastric Cancer, 2012, 15, 344-344.	5.3	16
70	Personality Trait and Quality of Life in Colorectal Cancer Survivors. Oncology Nursing Forum, 2011, 38, E221-E228.	1.2	15
71	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1481-1489.	1.1	15
72	High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. , 1999, 86, 415-420.		14

#	Article	IF	Citations
73	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemotherapy and Pharmacology, 2011, 68, 1387-1395.	2.3	14
74	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 799-806.	2.3	14
75	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. Journal of Clinical Oncology, 2017, 35, 4042-4042.	1.6	14
76	T-cell Malignant Lymphoma With Conjunctival Involvement. American Journal of Ophthalmology, 1998, 125, 717-719.	3.3	13
77	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer, 2014, 22, 1189-1197.	2.2	13
78	The B-cell-activating factor signalling pathway is associated withHelicobacter pyloriindependence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). Journal of Pathology, 2017, 241, 420-433.	4.5	13
79	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. Supportive Care in Cancer, 2017, 25, 533-539.	2.2	12
80	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)â€“based combinations in gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2019, 37, TPS467-TPS467.	1.6	12
81	Primary T Cell Leptomeningeal Lymphoma â€“ Successful Treatment with Systemic Chemotherapy. Oncology, 1995, 52, 501-504.	1.9	11
82	Young patients with colorectal cancer have increased risk of second primary cancers. Japanese Journal of Clinical Oncology, 2015, 45, 1029-1035.	1.3	11
83	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers, 2022, 14, 1005.	3.7	11
84	Longâ€term diseaseâ€free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by thirdâ€complementarityâ€determining regionâ€specific probes. British Journal of Haematology, 1995, 89, 914-916.	2.5	10
85	A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need. Japanese Journal of Clinical Oncology, 2020, 50, 693-700.	1.3	10
86	Relatively Low Expression of Multidrug Resistance-1 (MDR-1) and Its Possible Clinical Implication in Gastric Cancers. Journal of Clinical Gastroenterology, 1998, 26, 274-278.	2.2	10
87	Disseminated Mycobacterium kansasii infection in an HIV-negative patient presenting with mimicking multiple bone metastases. Diagnostic Microbiology and Infectious Disease, 2006, 54, 211-216.	1.8	9
88	Establishment of a novel MALT lymphoma cell line, maâ€1, from a patient with t(14;18)(q32;q21)â€positive Helicobacter Pyloriâ€independent Gastric MALT Lymphoma. Genes Chromosomes and Cancer, 2011, 50, 908-921.	2.8	9
89	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. Translational Oncology, 2013, 6, 363-369.	3.7	9
90	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6717-6725.	7.1	9

#	Article	IF	Citations
91	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer, 2022, 25, 207-217.	5.3	9
92	Minimal Toxicity to Myeloid Progenitor Cells of Weekly24-Hr Infusion of High-Dose 5-Fluorouracil: Direct Evidence from Colony Forming Unit-Granulocyte andMonocyte (CFU-GM) Clonogenic Assay. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 122-124.	0.0	9
93	Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy.. Journal of Clinical Oncology, 2016, 34, 134-134.	1.6	9
94	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. Journal of Clinical Oncology, 2020, 38, 4523-4523.	1.6	9
95	The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 667-667.	1.6	9
96	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Anticancer Research, 2018, 38, 1569-1577.	1.1	9
97	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anti-Cancer Drugs, 2007, 18, 703-708.	1.4	8
98	FrequentBRAFmutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome. Journal of Clinical Pathology, 2016, 69, 319-325.	2.0	8
99	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	2.8	8
100	A Pilot Study of Metabolomic Pathways Associated With Fatigue in Survivors of Colorectal Cancer. Biological Research for Nursing, 2021, 23, 42-49.	1.9	8
101	Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. Journal of Biomedical Science, 2021, 28, 75.	7.0	7
102	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Research, 2002, 22, 3621-7.	1.1	7
103	Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. Annals of Oncology, 2017, 28, iii10.	1.2	6
104	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. Oncology, 2019, 96, 156-163.	1.9	6
105	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Scientific Reports, 2021, 11, 9080.	3.3	6
106	Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. Medical Oncology, 2017, 34, 143.	2.5	6
107	Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study.. Journal of Clinical Oncology, 2017, 35, 700-700.	1.6	6
108	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. Anticancer Research, 2017, 37, 7095-7104.	1.1	6

#	Article	IF	Citations
109	Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. Anticancer Research, 2014, 34, 3695-9.	1.1	6
110	Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment. Oncology, 2005, 68, 350-355.	1.9	5
111	A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Cancer Chemotherapy and Pharmacology, 2011, 67, 1281-1289.	2.3	5
112	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 2004-2012.	2.8	5
113	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 2019, 118, 1024-1030.	1.7	5
114	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Haematologica, 2020, 105, e349-e354.	3.5	5
115	Recent advances in therapy for gastric cancer. Journal of the Formosan Medical Association, 2004, 103, 171-85.	1.7	5
116	Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Anti-Cancer Drugs, 2011, 22, 290-298.	1.4	4
117	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. Journal of the Formosan Medical Association, 2021, 120, 293-302.	1.7	4
118	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology, 2021, 10, 1973710.	4.6	4
119	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Journal of the Formosan Medical Association, 2021, 120, 2023-2031.	1.7	4
120	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-ÎºB-related signaling. Cancer Cell International, 2021, 21, 436.	4.1	4
121	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE, 2017, 12, e0180628.	2.5	4
122	Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. Anticancer Research, 2015, 35, 4207-14.	1.1	4
123	5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply. British Journal of Cancer, 1998, 77, 1711-1712.	6.4	3
124	Beware imposters: MAâ€‹1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large Bâ€‹cell lymphoma cell lineâ€”A reply: Despite the same 8â€‹code STR, MAâ€‹1 and Pfeiffer are cytogenetically diverse. Genes Chromosomes and Cancer, 2014, 53, 211-213.	2.8	3
125	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research, 2018, 38, 4805-4812.	1.1	3
126	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association, 2020, 119, 97-105.	1.7	3

#	Article	IF	Citations
127	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. Journal of Clinical Oncology, 2017, 35, 3567-3567.	1.6	3
128	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS215-TPS215.	1.6	3
129	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology, 2022, 40, TPS224-TPS224.	1.6	3
130	Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. Journal of the Formosan Medical Association, 2022, , .	1.7	3
131	High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. Breast Cancer Research and Treatment, 1998, 49, 237-244.	2.5	2
132	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anti-Cancer Drugs, 2005, 16, 739-742.	1.4	2
133	A pilot study of metabolomic pathways associated with fatigue in patients with colorectal cancer receiving chemotherapy. European Journal of Oncology Nursing, 2022, 56, 102096.	2.1	2
134	High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Anticancer Research, 2003, 23, 5133-7.	1.1	2
135	Minimal Toxicity to Myeloid Progenitor Cells of Weekly24â€Hr Infusion of Highâ€Dose 5â€Fluorouracil: Direct Evidence from Colony Forming Unitâ€Granulocyte andMonocyte (CFUâ€GM) Clonogenic Assay. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 122-124.	0.0	1
136	Recent Advances in the Treatment of Metastatic Colorectal Cancer in Taiwan. Journal of the Formosan Medical Association, 2011, 110, 1-3.	1.7	1
137	No evidence ofIGH-MALT1-translocation in the Ma-1 cell line-A reply. Genes Chromosomes and Cancer, 2013, 52, 593-594.	2.8	1
138	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. Journal of Cancer Research and Practice, 2017, 4, 72-75.	0.2	1
139	Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. British Journal of Cancer, 2021, 125, 48-54.	6.4	1
140	Regular statin users and colorectal cancer (CRC) prognosis.. Journal of Clinical Oncology, 2013, 31, 3554-3554.	1.6	1
141	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4099-4099.	1.6	1
142	Heterogeneous cell origin of Helicobater pylori-dependent high-grade gastric lymphomas.. Journal of Clinical Oncology, 2015, 33, e19520-e19520.	1.6	1
143	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. Journal of Clinical Oncology, 2015, 33, 697-697.	1.6	1
144	Spectrum of cancer patients receiving renal biopsy. Journal of the Formosan Medical Association, 2021, 121, 152-152.	1.7	0

#	Article	IF	Citations
145	Revisiting the Full Spectrum of Helicobacter pylori-Related Gastric Lymphoma. , 0, , .		0
146	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. Journal of Clinical Oncology, 2012, 30, 4081-4081.	1.6	0
147	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. Journal of Clinical Oncology, 2013, 31, 399-399.	1.6	0
148	Prevalence of gene amplifications of SOX-2, c-MET, and FGFR1 in Asian patients with esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, e15127-e15127.	1.6	0
149	Clinicopathologic features and treatment outcome of primary intestinal non-Hodgkin lymphoma: A single center experience.. Journal of Clinical Oncology, 2013, 31, e19523-e19523.	1.6	0
150	Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF-Î¹B pathway activation through inhibition of BAFF.. Journal of Clinical Oncology, 2013, 31, e13554-e13554.	1.6	0
151	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. Journal of Clinical Oncology, 2013, 31, e14501-e14501.	1.6	0
152	Risk of second primary malignancies in young patients with colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14533-e14533.	1.6	0
153	Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma.. Journal of Clinical Oncology, 2014, 32, 8571-8571.	1.6	0
154	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2015, 33, 158-158.	1.6	0
155	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	1.6	0
156	Primary tumor site as a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14592-e14592.	1.6	0
157	The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy.. Journal of Clinical Oncology, 2016, 34, 80-80.	1.6	0
158	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. Journal of Clinical Oncology, 2016, 34, e15695-e15695.	1.6	0
159	Association of the number of dissected lymph node (LN) with the survivals of locally advanced esophageal squamous cell carcinoma (ESCC) patients received preoperative chemoradiotherapy (CRT) followed by surgery.. Journal of Clinical Oncology, 2016, 34, e15543-e15543.	1.6	0
160	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma.. Journal of Clinical Oncology, 2016, 34, e19024-e19024.	1.6	0
161	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. Journal of Clinical Oncology, 2017, 35, 624-624.	1.6	0
162	A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.. Journal of Clinical Oncology, 2022, 40, TPS364-TPS364.	1.6	0